Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2016

View Archived Issues

EMA committee hands down positive opinion on Arzerra for relapsed CLL

Eagle Pharmaceuticals to acquire Arsia Therapeutics

European approval for Parsabiv to treat secondary hyperparathyroidism in hemodialysis patients

Combining Cas9 RNP with ssODN mediates efficient HSPC genome editing of sickle mutation

Eagle Pharmaceuticals initiates rolling NDA for Ryanodex in EHS

EMA adopts positive opinion for Novo Nordisk's Fiasp

EMA gives positive opinion on Gilead's MAA for Vemlidy

Ultragenyx Pharmaceutical withdraws conditional MAA from the EMA for Ace-ER

Recent Esteve patent describes sigma1 receptor ligands for pain

Harvard College reports insulin-degrading enzyme inhibitors

Constellation Pharmaceuticals prepares and tests LSD1 inhibitors

The Vanderbilt University discloses M1 receptor PAMs

Medshine Discovery presents JAK2 inhibitors

Interim phase I/II data presented on combination of lirilumab and nivolumab in head & neck cancer

Novel nanomedicine with alendronic acid corona shows promise for treatment of osteosarcoma

EMA's CHMP recommends approval of Suliqua

European Commission approves use of ustekinumab for Crohn's disease

Promising phase III topline results for CAM-2038 to treat moderate to severe opioid use disorder

Immune activation seen with CD122-biased cytokine NKTR-214 in cancer patients

OncBioMune updates progress in acquisition of Vitel Laboratorios

Blockade of H1R and H4R has additive effects in suppressing peanut-induced intestinal anaphylaxis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...